Stanford University is the heart of Silicon Valley in the United States, with a strong entrepreneurial atmosphere. Both students and researchers in various disciplines can find the source of innovation in this land. Stanford University's research scholars are constantly making breakthroughs and launching new technological achievements in an interdisciplinary collaborative atmosphere. Some choose to grant their patents to large pharmaceutical companies for conversion, while others choose to independently start their own businesses for further clinical research.
Dr. Zang Xiaoyu is the latter. She holds a PhD in molecular medicine from the Department of Chemistry at Stanford University. In 2013, she joined the research group of internationally renowned chemist and academician of the American Academy of Sciences, Paul A. Wender. Her research focuses on innovative drug delivery and delivery technologies, covering multiple popular fields such as peptides, egg white nanoparticles, and biocompatible polymer materials.
Incubation at Stanford University, gathering innovative forces from Silicon Valley, and the landing and transformation of over 20 years of scientific and technological achievements by academicians of the American Academy of Sciences
With the support of the Department of Chemistry and School of Medicine at Stanford University, Dr. Zang Xiaoyu and Academician Paul A. Wender established N1 Life in the United States, translating the technical achievements of the research group over 20 years into clinical practice. N1 Life has been incubated by Stanford University's official student incubator and the California School of Life Sciences.
Academician Paul A. Wender is a co-founder of N1 Life. He is a member of the American Academy of Sciences, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, the Royal Academy of Sciences of Spain, an internationally renowned chemist, outstanding educator, entrepreneur, and tenured professor at the Department of Chemistry and School of Medicine at Stanford University. The research group led by him was the first to invent the artificial synthesis of paclitaxel, which is also the shortest and most efficient synthesis path to date. He is also a continuous entrepreneur with many years of experience in the field of biomedicine, always prioritizing technology to serve people as his primary mission. At present, many companies based on the scientific research achievements of Wender's research group are carrying out transformation research in the clinical and preclinical stages, including the treatment of Alzheimer's disease, the development of tumor immunotherapy, the treatment of viral infectious diseases such as AIDS, and the development of new anti superbacteria drugs.
Engaging in the research and development of new drugs has always been Dr. Zang Xiaoyu's aspiration. In her opinion, the work of developing new drugs is equally important as doctors treating patients, and can help patients escape from their illnesses. So from her undergraduate studies until her doctoral studies, she has been persistently striving in this direction. "In the process of our doctoral research, we discovered an innovative delivery technology that has shown excellent delivery effects in animal experiments. Not only can it improve drug efficacy, but it can also reduce drug toxicity and side effects, and overcome multiple drug resistance." Dr. Zang Xiaoyu told ActionMai.com, "We hope to transform and implement this technology as soon as possible, so as to truly help more patients."
In 2019, N1 Life officially landed in Silicon Valley, USA, focusing on transforming biopharmaceutical technology from university research institutions to industrial applications, and collaborating with Stan
